Rein Therapeutics (NASDAQ:RNTX) Issues Quarterly Earnings Results

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, FiscalAI reports.

Rein Therapeutics Stock Performance

Shares of NASDAQ:RNTX opened at $0.55 on Monday. Rein Therapeutics has a 1-year low of $0.50 and a 1-year high of $2.10. The business’s 50 day moving average is $0.71 and its 200-day moving average is $1.01. The firm has a market capitalization of $47.63 million, a PE ratio of -0.32 and a beta of 1.47.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Maxim Group began coverage on Rein Therapeutics in a report on Monday, July 20th. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings cut Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Rein Therapeutics in a report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Check Out Our Latest Analysis on Rein Therapeutics

Institutional Trading of Rein Therapeutics

Large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in shares of Rein Therapeutics in the third quarter valued at approximately $127,000. Texas Capital Bank Wealth Management Services Inc increased its stake in Rein Therapeutics by 19.9% during the 3rd quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock worth $290,000 after purchasing an additional 60,000 shares in the last quarter. Rock Creek Group LLC grew its holdings in shares of Rein Therapeutics by 40.0% during the third quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock worth $141,000 after buying an additional 50,000 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in Rein Therapeutics in the second quarter valued at $260,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Rein Therapeutics during the 2nd quarter worth approximately $1,768,000. 90.89% of the stock is currently owned by institutional investors.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.

Featured Stories

Earnings History for Rein Therapeutics (NASDAQ:RNTX)

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.